TME Pharma NVXPAR:ALTME -3.45% FCF Yield % is -54.16 as of Jul. 11, 2026. The stock has 4 warning signs investors should review. Among 1,408 Biotechnology companies, TME Pharma NV ranks worse than 83.74% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
TME Pharma NV FCF Yield % Related Terms
TME Pharma NV FCF Yield % Historical Data
* Premium members only.
The historical data trend for TME Pharma NV's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XPAR:ALTME vs VRTX, REGN, ALNY: FCF Yield % Comparison
For the Biotechnology subindustry, TME Pharma NV's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TME Pharma NV FCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, TME Pharma NV's FCF Yield % distribution charts can be found below:
* The bar in red indicates where TME Pharma NV's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TME Pharma NV (XPAR:ALTME) has a FCF Yield % of -54.16 as of Jul. 11, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on TME Pharma NV and its competitors. According to the industry distribution chart, TME Pharma NV ranks #1179 out of 1408 companies in the Biotechnology industry, placing it in the top 83.7%.
Is TME Pharma NV's FCF Yield % too high?
TME Pharma NV's current FCF Yield % is -54.16. Based on the distribution chart, TME Pharma NV ranks #1179 out of 1408 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does TME Pharma NV's FCF Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, TME Pharma NV ranks #1179 out of 1408 companies for FCF Yield %. This places TME Pharma NV in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on TME Pharma NV and its competitors. TME Pharma NV's current FCF Yield % is -54.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TME Pharma NV stock overvalued right now?
TME Pharma NV (XPAR:ALTME) has a current FCF Yield % of -54.16. The current FCF Yield % is -54.16. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For TME Pharma NV (XPAR:ALTME), the current FCF Yield % is -54.16 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
TME Pharma NV is a clinical-stage biopharmaceutical company focused on developing novel therapies for treatment of the aggressive cancers and specializing in approaches targeting the tumor microenvironment. Its enhances the effectiveness of cancer treatments including current standards of care (such as antivascular agents, chemotherapy and radiotherapy) and immune-oncology approaches (such as immune checkpoint inhibitors). The company's Spiegelmer platform has generated a proprietary pipeline of clinical-stage product candidates including its cancer drug candidate NOX-A12 and its second clinical-stage asset, NOX-E36, now planned to be developed in eye diseases. The company has one segment active in pioneering the development of a new class of proprietary therapeutics called Spiegelmers.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAR:ALTME has been successfully added to your 